Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Nano World Summit: Current and Future Perspectives
Philadelphia | Pennsylvania | USA .

Day 1 :

OMICS International Nano World Summit 2018 International Conference Keynote Speaker Mahi R Singh photo

Mahi R Singh working as a professor since 1985 at The University of Western Ontario which is one best and largest Universities in Canada. He was a Royal Society Professor at Oxford University and worked in High Magnetic Lab in Toulouse. He was Chief researcher at Hitachi Research Lab in Tokyo. He also worked at McGill University, Montreal with P.R. Wallace who invented Graphene theoretically in 1947. He have very active research group and have produced many graduate students/postdocs who are professors all over the world. He have international theoretical and experimental collaborations in US, UK, Spain, Italy, Sweden, China, Germany, India, Egypt, Argentina, and Mexico. For example, He is developing collaboration with Klaus von Klitzing and he is visiting him next summer. Recently he have organized about 16 international conferences and hosted three Nobel Laureates (Klitzing, Leggatt and Yonah). He have been invited as plenary and invited speaker throughout the word. Since 2003, he have presented about 100 public, plenary and invited talks in many international conferences and universities in the world. He has published about 300 papers and 10 books in condensed matter physics, optoelectronics, plasmonics, nanophotonics, nanomaterials, nano-hybrids and metamaterials.


Noble-metal nanoparticles are known to enhance emission rates of quantum emitters (QEs) significantly by decreasing their radiative lifetime and increasing their quantum yield. The enhancement of the emission in QEs such as molecular fluorophores is a highly useful strategy for improving detection sensitivity and selectivity in many emerging applications in medicine, and DNA screening. Recently, there is considerable interest to study hybrid systems made of biocompatible fluorescent molecules and metallic double nanoshells (DNSs) for biomedical imaging and for the detection of disease markers in the near-infrared wavelength region. The penetration depth of near-infrared light is large in most biological media. It is found that these hybrids have large absorption coefficients and high quantum yields in the far-infrared region. Here, we study the light emission from quantum emitter and double metallic nanoshell hybrid systems. Quantum emitters act as local sources which transmit their light efficiently due to double nanoshell near field. The double nanoshell consist a dielectric core and two outer nanoshells. The first nanoshell is made of a metal and the second spacer nanoshell is made of a dielectric material or human serum albumin. We have calculated the fluorescence emission for a quantum emitter-double nanoshell hybrid when it is injected in an animal or human body. Surface plasmon polariton resonances in the double nanoshell are calculated using Maxwell’s equations in the quasi-static approximation and the fluorescence emission is evaluated using the density matrix method in the presence of dipole-dipole interactions. We have compared our theory with two fluorescence experiments in hybrid systems in which the quantum emitter is Indocyanine Green or infrared fluorescent molecules. The outer spacer nanoshell of double metallic nanoshells consists of silica and human serum albumin with variable thickness. Our theory explains the enhancement of fluorescence spectra in both experiments. We find that the thickness of the spacer nanoshell layer increases the enhancement when the fluorescence decreases. The enhancement of the fluorescence depends on the type of quantum emitter, spacer layer and double nanoshell. We also found that the peak of the fluorescence spectrum can be shifted by changing the shape and size of the nanoshell. The fluorescence spectra can be switched from one peak to two peaks by removing the degeneracy of excitonic states in the quantum emitter. Hence using these properties, one can use these hybrids as sensing and switching devices for applications in medicine.

Keynote Forum

Esmaiel Jabbari

University of South Carolina,Columbia, USA

Keynote: Nanomaterials for drug targeting to cancer stem cells
OMICS International Nano World Summit 2018 International Conference Keynote Speaker Esmaiel Jabbari photo

Esmaiel Jabbari has completed his PhD in Chemical Engineering from Purdue University. He is Tenured Full Professor of Chemical and Biomedical Engineering at the University of South Carolina. His biomaterials, tissue engineering, and drug delivery laboratory specializes in creation of 3D tissue models for skeletal tissue engineering and cancer drug delivery. He is the Author of >260 research articles. He has received Berton Rahn Award from AO Foundation and Stephen Milam Award from Oral and Maxillofacial Surgery Foundation. He was elected to the College of Fellows of AIMBE in 2013. He serves as Academic Editor for PLOS ONE.


A major contributing factor to mortality in cancer patients is relapse after surgery and targeted therapy, and developing resistance to therapy. Breast cancer recurrence affects 30% of the patients. Cancer recurrence and resistance is related to the existence of a very small population of initiating cells or stem cells (CSCs) in the tumor tissue with high expression of ATP-binding cassette (ABC) transporter proteins associated with drug resistance. After therapy, the bulk of tumor shrinks to <1% of its initial volume and the tumor tissue becomes enriched with CSCs that are highly resistant to conventional therapies. Further, as much as 40% of the volume of solid tumors is occupied by tumor-associated macrophages (TAMs), specifically immunosuppressive M2-macrophages, which play a central role in cancer progression. One approach to overcome carrier-mediated drug resistance in CSCs is to use nanoparticles (NPs) for drug encapsulation and intracellular delivery by endocytosis. Unlike drug molecules in which their uptake is affected by up-regulation of ABC transporter proteins, NPs utilize macropinocytosis, clathrin- and caveolin-mediated endocytosis for transcellular cell uptake. Although the uptake of NPs by the mononuclear phagocyte system (MPS) and NPs’ enhanced permeation and retention in the tumor tissue is extensively investigated, little is known about the role of TAMs on uptake and toxicity of drug-loaded NPs toward CSC sub-population of cancer cells. I will present experimental results related to the effect of macrophages on toxicity of drug conjugated to polyhedral oligosilsesquioxane (POSS) NPs toward breast cancer cells within a novel three-dimensional CSC-enriching culture system.

OMICS International Nano World Summit 2018 International Conference Keynote Speaker Thomas J Webster photo

Thomas J Webster has completed his BS in Chemical Engineering from the University of Pittsburgh (1995) and MS in Biomedical Engineering from RPI (1997) and PhD in the year of 2000. Currently, he is the Director of the Nanomedicine Laboratories. He has Supervised over 149 Visiting Faculty, Fellows, Post-doctoral, and thesis completing students. He is the Founding Editor-In-Chief of the International Journal of Nanomedicine (impact factor of 5.03) and directs or co-directs three international centers. He is a fellow of numerous societies, former President of the US Society for Biomaterials, and has started 11 companies with four FDA products.


There is an acute shortage of organs due to disease, trauma, congenital defects, and most importantly, age related maladies. The synthetic materials used in tissue engineering applications today are typically composed of millimeter or micron sized particles and/or fiber dimensions. Although human cells are on the micron scale, their individual components, e.g. proteins, are composed of nanometer features. By modifying only the nanofeatures on material surfaces without changing surface chemistry, it is possible to increase tissue growth of any human tissue by controlling the endogenous adsorption of adhesive proteins onto the material surface. In addition, our group has shown that these same nanofeatures and nano-modifications can reduce bacterial growth without using antibiotics, which may further accelerate the growth of antibiotic resistant microbes. Inflammation can also be decreased through the use of nanomaterials. Finally, nanomedicine has been shown to stimulate the growth and differentiation of stem cells, which may someday be used to treat incurable disorders, such as neural damage. This strategy also accelerates FDA approval and commercialization efforts since new chemistries are not proposed, rather chemistries already approved by the FDA with altered nanoscale features. This invited talk will highlight some of the advancements and emphasize current nanomaterials approved by the FDA for human implantation and discuss the future role of implantable sensors in preventing, diagnosing and treating disease.